OTCMKTS:ICOTFiCo Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding iCo Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.04 +0.01 (+25.27 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$0.04Now: $0.04▼$0.0450-Day Range$0.02MA: $0.03▼$0.0452-Week Range$0.02Now: $0.04▼$0.11Volume600 shsAverage Volume52,090 shsMarket Capitalization$5.41 millionP/E RatioN/ADividend YieldN/ABeta2.89 ProfileAdvanced ChartCompetitorsEarningsHeadlinesSocial Media iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for iCo Therapeutics. Previous Next 2.6 Community Rank Outperform VotesiCo Therapeutics has received 69 “outperform” votes. (Add your “outperform” vote.)Underperform VotesiCo Therapeutics has received 64 “underperform” votes. (Add your “underperform” vote.)Community SentimentiCo Therapeutics has received 51.88% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about iCo Therapeutics and other stocks. Vote “Outperform” if you believe ICOTF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ICOTF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldiCo Therapeutics does not currently pay a dividend.Dividend GrowthiCo Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iCo Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of iCo Therapeutics is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iCo Therapeutics is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ICOTF Previous Symbol CUSIPN/A CIKN/A Webwww.icotherapeutics.com Phone778-802-9806Debt Debt-to-Equity RatioN/A Current Ratio4.37 Quick Ratio4.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-3.52Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-1,450,000.00 Net MarginsN/A Return on Equity-449.33% Return on Assets-183.51%Miscellaneous EmployeesN/A Outstanding Shares153,747,000Market Cap$5.41 million Next Earnings Date6/4/2020 (Estimated) OptionableNot Optionable OTC:ICOTF Rates by TradingView Receive ICOTF News and Ratings via Email Sign-up to receive the latest news and ratings for ICOTF and its competitors with MarketBeat's FREE daily newsletter. iCo Therapeutics (OTCMKTS:ICOTF) Frequently Asked Questions How has iCo Therapeutics' stock been impacted by COVID-19 (Coronavirus)? iCo Therapeutics' stock was trading at $0.0314 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ICOTF shares have increased by 12.1% and is now trading at $0.0352. View which stocks have been most impacted by Coronavirus. When is iCo Therapeutics' next earnings date? iCo Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for iCo Therapeutics. How were iCo Therapeutics' earnings last quarter? iCo Therapeutics Inc (OTCMKTS:ICOTF) posted its earnings results on Friday, May, 15th. The biotechnology company reported ($0.01) EPS for the quarter. View iCo Therapeutics' earnings history. Has iCo Therapeutics been receiving favorable news coverage? Media stories about ICOTF stock have been trending negative on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. iCo Therapeutics earned a coverage optimism score of -2.4 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutiCo Therapeutics. Who are some of iCo Therapeutics' key competitors? Some companies that are related to iCo Therapeutics include Adial Pharmaceuticals (ADIL), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Unum Therapeutics (UMRX), Tetraphase Pharmaceuticals (TTPH), Mateon Therapeutics (MATN), Intec Pharma (NTEC), Regulus Therapeutics (RGLS), GT Biopharma (GTBP), Integrated BioPharma (INBP), Novelion Therapeutics (NVLNF), Salarius Pharmaceuticals (SLRX), KemPharm (KMPH), Uluru (ULUR), Novelion Therapeutics (NVLN) and Cellectar Biosciences (CLRB). View all competitors. Who are iCo Therapeutics' key executives? iCo Therapeutics' management team includes the following people: Mr. Andrew J. Rae M.B.A., BSc, MBA, Co-Founder, CEO, Pres & Director (Age 52)Mr. Michael Liggett CPA, CA, Bsc. Pharm., CFO, Corp. Sec. & Director (Age 59)Dr. Peter Hnik M.D., MHSc, Chief Medical Officer (Age 63) What is iCo Therapeutics' stock symbol? iCo Therapeutics trades on the OTCMKTS under the ticker symbol "ICOTF." How do I buy shares of iCo Therapeutics? Shares of ICOTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is iCo Therapeutics' stock price today? One share of ICOTF stock can currently be purchased for approximately $0.04. How big of a company is iCo Therapeutics? iCo Therapeutics has a market capitalization of $5.41 million. What is iCo Therapeutics' official website? The official website for iCo Therapeutics is www.icotherapeutics.com. How can I contact iCo Therapeutics? iCo Therapeutics' mailing address is 777 Hornby Street 6th Floor, Vancouver A1, V6Z 1S4. The biotechnology company can be reached via phone at 778-802-9806 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
